The HCV World CAB interacted with pharmaceutical and diagnostics companies that produce HCV treatment and tests to understand their access, licensing, and pricing strategies, particularly in high-burden, low- and middle-income countries.
Materials in this section
Treatment activists held the first global LMIC-focused dialogue with pharmaceutical companies that produce HCV treatment, co-organized by TAG and the Asia Pacific Network of PLHA. More
Treatment activists met with generics and diagnostics companies to present demands and obtain strategic information from companies on critical access issues in low- and middle-income countries. More
Activists’ demonstrations demanding affordable hepatitis C treatment and universal access to generic medicines everywhere. More